Can a migraine drug stop Post-Concussion headaches?
NCT ID NCT04098250
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 38 times
Summary
This small study tested whether the drug erenumab (Aimovig) can prevent persistent headaches after a mild traumatic brain injury. Six adults with recent post-traumatic headache were given either erenumab or a placebo. The goal was to see if the drug could reduce the number of moderate-to-severe headache days over 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST TRAUMATIC HEADACHE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55901, United States
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Phoenix VA Health Care System
Phoenix, Arizona, 85012, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Erenumab (Aimovig)
What this could lead to
If it works, this could point toward a treatment to prevent post-traumatic headaches from becoming chronic after a mild brain injury.
What could go wrong
This is a very small, early-phase trial with only 6 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.